Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform

International Journal of Cancer. Journal International Du Cancer
N L Van HalR H Brakenhoff

Abstract

At present, tumor-targeting with monoclonal antibodies (MAbs) is among the most promising novel adjuvant-therapy modalities for the treatment of patients with minimal residual disease of head-and-neck squamous-cell carcinoma (HNSCC). For this purpose we developed MAb U36, recognizing a 200-kDa antigen expressed on the outer cell surface of squamous-cell carcinomas and their normal counterparts. Clinical radioimmunoscintigraphy (RIS) and biodistribution studies have shown that the MAb-U36-defined antigen is a suitable target molecule for antibody-based therapy of head-and-neck cancer. In the present study we further characterized the antigen by cDNA cloning. The cDNA was isolated by expression cloning in COS-7 cells. Sequence analysis and database searching revealed that the MAb-U36-defined antigen is identical to the squamous-cell-specific CD44 splice variant epican. The epitope recognized by MAb U36 was mapped by screening overlapping synthetic peptides of the epican-specific region encoded by exon 7-11 (v3-v7), and appeared to be located in the v6 domain. The applicability of MAb U36 for targeting human tumors of various origin expressing the CD44v6 domain is discussed.

References

Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·G R ScreatonJ I Bell
Jan 1, 1990·Methods in Enzymology·F W StudierJ W Dubendorff
Sep 24, 1987·Journal of Immunological Methods·H M GeysenP G Schoofs
Feb 4, 1995·Lancet·K KoretzC Herfarth
May 13, 1995·Lancet·K FriedrichsU Günthert
Feb 4, 1995·Lancet·R B Stricker, B Goldberg
Jan 1, 1994·Infectious Diseases in Obstetrics and Gynecology·V R BohmanK J Leveno

❮ Previous
Next ❯

Citations

Sep 17, 2015·Expert Opinion on Therapeutic Targets·Ibrahim H Sahin, Jim Klostergaard
May 25, 2012·Expert Opinion on Therapeutic Targets·Sukhen C GhoshJim Klostergaard
Mar 4, 1998·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·G A van Dongen, G B Snow
Oct 15, 2009·Head & Neck·Marika V Nestor
Jan 25, 2002·Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists·G J Thomas, P M Speight
Jun 25, 1998·International Journal of Cancer. Journal International Du Cancer·F B van GogG A van Dongen
Apr 20, 2004·Cancer Immunology, Immunotherapy : CII·Thomas K HoffmannTheresa L Whiteside
May 7, 2002·International Journal of Cancer. Journal International Du Cancer·Iris VerelGuus A M S van Dongen
Feb 6, 2007·European Journal of Nuclear Medicine and Molecular Imaging·Marc-André FortinHans Lundqvist
May 12, 2018·Journal of Hematology & Oncology·Chen ChenJames W Freeman
Dec 5, 2014·Archives of Toxicology·V Orian-Rousseau, H Ponta
Aug 14, 1999·International Journal of Cancer. Journal International Du Cancer·N L van HalR H Brakenhoff
Nov 4, 2017·Contrast Media & Molecular Imaging·Diana Spiegelberg, Johan Nilvebrant
Jan 12, 2000·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·B J FolzJ A Werner
Jan 21, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Krishan Kumar, Arijit Ghosh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.